These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24935082)

  • 1. Sequential treatment with fluoxetine and relapse--prevention CBT to improve outcomes in pediatric depression.
    Kennard BD; Emslie GJ; Mayes TL; Nakonezny PA; Jones JM; Foxwell AA; King J
    Am J Psychiatry; 2014 Oct; 171(10):1083-90. PubMed ID: 24935082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continued Effectiveness of Relapse Prevention Cognitive-Behavioral Therapy Following Fluoxetine Treatment in Youth With Major Depressive Disorder.
    Emslie GJ; Kennard BD; Mayes TL; Nakonezny PA; Moore J; Jones JM; Foxwell AA; King J
    J Am Acad Child Adolesc Psychiatry; 2015 Dec; 54(12):991-8. PubMed ID: 26598474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder.
    Kennard BD; Emslie GJ; Mayes TL; Nightingale-Teresi J; Nakonezny PA; Hughes JL; Jones JM; Tao R; Stewart SM; Jarrett RB
    J Am Acad Child Adolesc Psychiatry; 2008 Dec; 47(12):1395-404. PubMed ID: 18978634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
    March JS; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J
    Arch Gen Psychiatry; 2007 Oct; 64(10):1132-43. PubMed ID: 17909125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder.
    Perlis RH; Nierenberg AA; Alpert JE; Pava J; Matthews JD; Buchin J; Sickinger AH; Fava M
    J Clin Psychopharmacol; 2002 Oct; 22(5):474-80. PubMed ID: 12352270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).
    Kennard B; Silva S; Vitiello B; Curry J; Kratochvil C; Simons A; Hughes J; Feeny N; Weller E; Sweeney M; Reinecke M; Pathak S; Ginsburg G; Emslie G; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1404-11. PubMed ID: 17135985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial.
    Bondar J; Caye A; Chekroud AM; Kieling C
    Lancet Psychiatry; 2020 Apr; 7(4):337-343. PubMed ID: 32199509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression.
    Dunlop BW; LoParo D; Kinkead B; Mletzko-Crowe T; Cole SP; Nemeroff CB; Mayberg HS; Craighead WE
    Am J Psychiatry; 2019 Apr; 176(4):275-286. PubMed ID: 30764648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
    Davey CG; Chanen AM; Hetrick SE; Cotton SM; Ratheesh A; Amminger GP; Koutsogiannis J; Phelan M; Mullen E; Harrison BJ; Rice S; Parker AG; Dean OM; Weller A; Kerr M; Quinn AL; Catania L; Kazantzis N; McGorry PD; Berk M
    Lancet Psychiatry; 2019 Sep; 6(9):735-744. PubMed ID: 31371212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents.
    Emslie GJ; Kennard BD; Mayes TL; Nightingale-Teresi J; Carmody T; Hughes CW; Rush AJ; Tao R; Rintelmann JW
    Am J Psychiatry; 2008 Apr; 165(4):459-67. PubMed ID: 18281410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    March J; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J;
    JAMA; 2004 Aug; 292(7):807-20. PubMed ID: 15315995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial.
    DeRubeis RJ; Zajecka J; Shelton RC; Amsterdam JD; Fawcett J; Xu C; Young PR; Gallop R; Hollon SD
    JAMA Psychiatry; 2020 Mar; 77(3):237-245. PubMed ID: 31799993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine.
    Petersen T; Harley R; Papakostas GI; Montoya HD; Fava M; Alpert JE
    Psychol Med; 2004 Apr; 34(3):555-61. PubMed ID: 15259840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of safety and long-term outcomes of initial treatment with placebo in TADS.
    Kennard BD; Silva SG; Mayes TL; Rohde P; Hughes JL; Vitiello B; Kratochvil CJ; Curry JF; Emslie GJ; Reinecke MA; March JS;
    Am J Psychiatry; 2009 Mar; 166(3):337-44. PubMed ID: 19147693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy.
    Rohde P; Silva SG; Tonev ST; Kennard BD; Vitiello B; Kratochvil CJ; Reinecke MA; Curry JF; Simons AD; March JS
    Arch Gen Psychiatry; 2008 Apr; 65(4):447-55. PubMed ID: 18391133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).
    Curry J; Rohde P; Simons A; Silva S; Vitiello B; Kratochvil C; Reinecke M; Feeny N; Wells K; Pathak S; Weller E; Rosenberg D; Kennard B; Robins M; Ginsburg G; March J;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1427-39. PubMed ID: 17135988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo.
    Jarrett RB; Minhajuddin A; Gershenfeld H; Friedman ES; Thase ME
    JAMA Psychiatry; 2013 Nov; 70(11):1152-60. PubMed ID: 24005123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks.
    March J; Silva S; Vitiello B;
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1393-403. PubMed ID: 17135984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors and Moderators of Relapse in Children and Adolescents With Major Depressive Disorder.
    Kennard BD; Mayes TL; Chahal Z; Nakonezny PA; Moorehead A; Emslie GJ
    J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29474007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder.
    Vittengl JR; Clark LA; Thase ME; Jarrett RB
    J Consult Clin Psychol; 2014 Dec; 82(6):1049-59. PubMed ID: 25045908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.